JP2013502461A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013502461A5 JP2013502461A5 JP2012526892A JP2012526892A JP2013502461A5 JP 2013502461 A5 JP2013502461 A5 JP 2013502461A5 JP 2012526892 A JP2012526892 A JP 2012526892A JP 2012526892 A JP2012526892 A JP 2012526892A JP 2013502461 A5 JP2013502461 A5 JP 2013502461A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- acetylcysteine
- disulfonyl
- composition according
- pharmaceutically effective
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 17
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims 8
- 229960004308 acetylcysteine Drugs 0.000 claims 8
- JYIYPKOJFKMEKS-UHFFFAOYSA-N n-(2,2-dimethyl-1-phenylpropylidene)hydroxylamine Chemical compound CC(C)(C)C(=NO)C1=CC=CC=C1 JYIYPKOJFKMEKS-UHFFFAOYSA-N 0.000 claims 7
- 206010011891 Deafness neurosensory Diseases 0.000 claims 4
- 208000009966 Sensorineural Hearing Loss Diseases 0.000 claims 4
- 230000037396 body weight Effects 0.000 claims 4
- 231100000879 sensorineural hearing loss Toxicity 0.000 claims 4
- 208000023573 sensorineural hearing loss disease Diseases 0.000 claims 4
- RDHQFKQIGNGIED-MRVPVSSYSA-N O-acetyl-L-carnitine Chemical compound CC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C RDHQFKQIGNGIED-MRVPVSSYSA-N 0.000 claims 3
- WZXBYDBYBIGAQN-UWVGGRQHSA-N (2s)-2-amino-5-[[(2r)-1-(carboxymethylamino)-3-(diethylcarbamoylsulfanyl)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid Chemical compound CCN(CC)C(=O)SC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O WZXBYDBYBIGAQN-UWVGGRQHSA-N 0.000 claims 2
- JKRODHBGNBKZLE-YUMQZZPRSA-N (2s)-2-amino-5-[[(2r)-1-[(2-ethoxy-2-oxoethyl)amino]-1-oxo-3-sulfanylpropan-2-yl]amino]-5-oxopentanoic acid Chemical compound CCOC(=O)CNC(=O)[C@H](CS)NC(=O)CC[C@H](N)C(O)=O JKRODHBGNBKZLE-YUMQZZPRSA-N 0.000 claims 2
- FFEARJCKVFRZRR-SCSAIBSYSA-N D-methionine Chemical compound CSCC[C@@H](N)C(O)=O FFEARJCKVFRZRR-SCSAIBSYSA-N 0.000 claims 2
- 229930182818 D-methionine Natural products 0.000 claims 2
- 206010011903 Deafness traumatic Diseases 0.000 claims 2
- DYEFUKCXAQOFHX-UHFFFAOYSA-N Ebselen Chemical compound [se]1C2=CC=CC=C2C(=O)N1C1=CC=CC=C1 DYEFUKCXAQOFHX-UHFFFAOYSA-N 0.000 claims 2
- 208000002946 Noise-Induced Hearing Loss Diseases 0.000 claims 2
- 108700024319 S-ethyl glutathione Proteins 0.000 claims 2
- 230000001154 acute effect Effects 0.000 claims 2
- 108700006011 carbamathione Proteins 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 229950010033 ebselen Drugs 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 238000007920 subcutaneous administration Methods 0.000 claims 2
- 239000003963 antioxidant agent Substances 0.000 claims 1
- 230000003078 antioxidant effect Effects 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27411809P | 2009-08-24 | 2009-08-24 | |
| US61/274,118 | 2009-08-24 | ||
| PCT/US2010/046420 WO2011028503A1 (en) | 2009-08-24 | 2010-08-24 | Methods for treating acute acoustic trauma |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015116630A Division JP6038233B2 (ja) | 2009-08-24 | 2015-06-09 | 急性音響外傷の治療方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013502461A JP2013502461A (ja) | 2013-01-24 |
| JP2013502461A5 true JP2013502461A5 (https=) | 2013-10-03 |
| JP5762414B2 JP5762414B2 (ja) | 2015-08-12 |
Family
ID=43649578
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012526892A Active JP5762414B2 (ja) | 2009-08-24 | 2010-08-24 | 急性音響外傷の治療方法 |
| JP2015116630A Active JP6038233B2 (ja) | 2009-08-24 | 2015-06-09 | 急性音響外傷の治療方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015116630A Active JP6038233B2 (ja) | 2009-08-24 | 2015-06-09 | 急性音響外傷の治療方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US10555915B2 (https=) |
| EP (1) | EP2470015B1 (https=) |
| JP (2) | JP5762414B2 (https=) |
| AU (1) | AU2010289838C1 (https=) |
| CA (1) | CA2772097C (https=) |
| ES (1) | ES2563777T3 (https=) |
| IL (1) | IL218302A (https=) |
| WO (1) | WO2011028503A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3258955A1 (en) * | 2015-02-20 | 2017-12-27 | Institut Pasteur | Prevention and/or treatment of hearing loss or impairment |
| US20180256756A1 (en) * | 2015-09-18 | 2018-09-13 | Oklahoma Medical Research Foundation | Method of transporting an agent across blood-brain, blood-cochlear or blood-cerebrospinal fluid barrier |
| TWI642431B (zh) * | 2016-10-28 | 2018-12-01 | 西德有機化學藥品股份有限公司 | Ｎ－乙醯半胱胺酸用於治療突發性感覺神經性聽力損失的方法 |
| US10576125B2 (en) * | 2016-10-31 | 2020-03-03 | Hough Ear Institute | Methods for enhancing synaptogenesis and neuritogenesis |
| EP3570826A4 (en) * | 2017-01-19 | 2020-09-23 | Otologic Pharmaceutics, Inc. | N-ACETYLCYSTEIN FORMULATIONS AND THEIR USES |
| JP6999896B2 (ja) | 2017-09-21 | 2022-01-19 | 学校法人慶應義塾 | 音響外傷難聴モデル動物の作製方法及びそれにより作製される音響外傷難聴モデル動物 |
| EP3787750A1 (en) * | 2018-05-03 | 2021-03-10 | Hough Ear Institute | Methods for reducing accumulated pathologic tau protein |
| US12121501B2 (en) | 2018-09-12 | 2024-10-22 | Hough Ear Institute | Methods for treating hearing loss incident to cochlear implant surgery |
| US11857551B1 (en) | 2020-07-10 | 2024-01-02 | Ting Therapeutics Llc | Methods for the prevention and treatment of hearing loss |
| EP4309655A1 (en) * | 2022-07-22 | 2024-01-24 | Consejo Superior de Investigaciones Científicas (CSIC) | Quinolylnitrone derivatives for use in the prevention and/or treatment of hearing loss |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5488145A (en) * | 1993-12-23 | 1996-01-30 | Oklahoma Medical Research Foundation | 2,4-disulfonyl phenyl butyl nitrone, its salts, and their use as pharmaceutical free radical traps |
| US6649621B2 (en) * | 1997-12-16 | 2003-11-18 | The United States Of America As Represented By The Secretary Of The Navy | Prevention or reversal of sensorineural hearing loss (SNHL) through biologic mechanisms |
| US6177434B1 (en) * | 1997-12-16 | 2001-01-23 | The United States Of America As Represented By The Secretary Of The Navy | Prevention or reversal of sensorineural hearing loss (SNHL) through biologic mechanisms |
| US6469049B1 (en) | 2000-04-21 | 2002-10-22 | The United States Of America As Represented By The Secretary Of The Army | Method of treating, preventing or inhibiting central nervous system injuries and diseases |
| SE0001916D0 (sv) * | 2000-05-23 | 2000-05-23 | Astrazeneca Ab | Novel formulation |
| WO2004096256A1 (en) * | 2001-01-23 | 2004-11-11 | The United States Of America, As Represented By The Secretary Of The Navy | Methods for preventing and treating loss of balance function due to oxidative stress |
| US7700111B2 (en) | 2002-01-17 | 2010-04-20 | The Regents Of The University Of Michigan | Auditory nerve protection and re-growth |
| WO2005016243A2 (en) * | 2003-06-09 | 2005-02-24 | Pharmacia Corporation | Compositions of a cyclooxygenase-2 selective inhibitor and an antioxidant agent for the treatment of central nervous system disorders |
| US20050182060A1 (en) | 2004-02-13 | 2005-08-18 | Kelly Michael G. | 2-Substituted and 4-substituted aryl nitrone compounds |
| TW200812567A (en) * | 2006-03-29 | 2008-03-16 | Kaneka Corp | Agent for improving nervous system cell functions |
| JP5236641B2 (ja) * | 2006-07-25 | 2013-07-17 | ハフ イヤ インスティテュート | 急性音響外傷の治療方法 |
| BRPI0716143A2 (pt) * | 2006-08-29 | 2013-11-26 | Genentech Inc | Uso de tenecteplase para tratar derrame isquêmico agudo |
| US20100234402A1 (en) * | 2007-05-31 | 2010-09-16 | Gideon Dreyfuss | Methods and compositions for treating spinal muscular atrophy |
| EP2278999B1 (en) | 2008-04-21 | 2025-01-29 | Dompé farmaceutici S.p.A. | Auris formulations for treating otic diseases and conditions |
| KR20140069014A (ko) | 2011-09-06 | 2014-06-09 | 사우스웨스트 나노테크놀로지스, 인크. | 단일벽 탄소 나노튜브 정제 방법 및 개선된 단일벽 탄소 나노튜브 |
-
2010
- 2010-08-24 EP EP10814226.6A patent/EP2470015B1/en active Active
- 2010-08-24 WO PCT/US2010/046420 patent/WO2011028503A1/en not_active Ceased
- 2010-08-24 CA CA2772097A patent/CA2772097C/en active Active
- 2010-08-24 US US13/391,772 patent/US10555915B2/en active Active
- 2010-08-24 JP JP2012526892A patent/JP5762414B2/ja active Active
- 2010-08-24 AU AU2010289838A patent/AU2010289838C1/en active Active
- 2010-08-24 ES ES10814226.6T patent/ES2563777T3/es active Active
-
2012
- 2012-02-23 IL IL218302A patent/IL218302A/en active IP Right Grant
-
2015
- 2015-06-09 JP JP2015116630A patent/JP6038233B2/ja active Active
-
2017
- 2017-04-24 US US15/495,897 patent/US20170224635A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013502461A5 (https=) | ||
| EA201071054A1 (ru) | Твердый препарат, растворяющийся во рту | |
| CA2753382C (en) | Hepatitis c virus inhibitors | |
| TN2012000358A1 (en) | Hepatitis c virus inhibitors | |
| EP2555622A4 (en) | HEPATITIS C-VIRUS HEMMER | |
| EP2368900A3 (en) | Inhibitors of serine proteases, particularly hcv ns3-ns4a protease | |
| WO2008022006A3 (en) | Arylalkoxyl hepatitis c virus protease inhibitors | |
| JP2011527299A5 (https=) | ||
| JP2013507423A5 (https=) | ||
| WO2009076166A3 (en) | Oximyl hcv serine protease inhibitors | |
| WO2009076173A3 (en) | Fluorinated tripeptide hcv serine protease inhibitors | |
| WO2008019289A3 (en) | Tetrazolyl macrocyclic hepatitis c serine protease inhibitors | |
| JP2012512907A5 (https=) | ||
| JP2010077141A5 (https=) | ||
| WO2008021960A3 (en) | Triazolyl macrocyclic hepatitis c serine protease inhibitors | |
| TW200833663A (en) | Therapeutic agents | |
| WO2007143694A3 (en) | Macrocyclic oximyl hepatitis c protease inhibitors | |
| JP2013518107A5 (https=) | ||
| EP2311851A3 (en) | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease | |
| UA102677C2 (uk) | Хіноксалінвмісні сполуки як інгібітори вірусу гепатиту с | |
| WO2008021871A3 (en) | Triazolyl acyclic hepatitis c serine protease inhibitors | |
| EP2374464A3 (en) | HCV N3S-NS4A protease inhibition | |
| JP2013537905A5 (https=) | ||
| WO2009135179A3 (en) | The use of solid carrier particles to improve the processability of a pharmaceutical agent | |
| NZ606888A (en) | Pharmaceutical compositions for the treatment of diabetes mellitus |